Evolving Mutations in Metastatic Breast Cancer

Evolving Mutations in Metastatic Breast Cancer

Dr. Utthara Nayar talks about finding a way to overcome hormonal therapy resistance in hormone receptor-positive metastatic breast cancer.
May 8, 2018
/_next/static/media/art.743baba8.png
00:00
Download
00:00

At the 2018 American Association for Cancer Research Annual Meeting, Dr. Nayar presented research looking at how acquired HER2 mutations can make some metastatic hormone receptor-positive breast cancers resistant to hormonal therapy.

Listen to the podcast to hear Dr. Nayar explain:

  • the number of metastatic hormone receptor-positive breast cancers that become resistant to hormonal therapy

  • what whole exome sequencing is and why she and her colleagues used it in this study

  • the possibility that genetic sequencing of cancers could be an ongoing part of treatment at some point in the future

About the guest
 
Utthara Nayar headshot
Utthara Nayar, PhD

Dr. Utthara Nayar is a research fellow in medicine at the Dana-Farber Cancer Institute, the Harvard Medical School, and the Broad Institute of MIT and Harvard. A cancer biologist, her broad research focuses on the interface of basic biology, targeted medicines, and drug resistance.

— Last updated on June 29, 2022, 2:49 PM

 
Lilly

This content made possible by Lilly Oncology.

 
 
Support Breastcancer.org to produce more content like this

Your donation goes directly to what you read, hear, and see on Breastcancer.org.

Donate